Articles and Videos
Loading...
November 8, 2021
The importance of identifying the specific pharmacological effect of each of cannabinoid
InMed CEO Eric A. Adams discusses the treatment potential of cannabinoids and the importance of identifying the specific pharmacological effect of each of the cannabinoids...
Source:
The Dales Report
November 8, 2021
InMed’s recent research leads to a patent application of a rare cannabinoid as a potential treatment option for neurodegenerative diseases
Shadd Dales of The Dales Report speaks with InMed CEO Eric A. Adams about InMed’s recent research that led to a patent application demonstrating neuroprotection...
Source:
The Dales Report
November 8, 2021
How InMed will leverage its multiple cannabinoid manufacturing technologies
The Dales Report spoke with InMed Pharmaceuticals CEO, Eric A. Adams, about InMed’s recent acquisition of rare cannabinoid manufacturer, BayMedica, and how InMed will leverage...
Source:
The Dales Report
November 8, 2021
How the acquisition of GW Pharma changed the landscape of the cannabinoid industry and the opportunities within the sector.
Shadd Dales of The Dales Report speaks with InMed CEO Eric A. Adams to talk about the acquisition of GW Pharma by Jazz Pharmaceuticals and...
Source:
The Dales Report
November 8, 2021
The commercial importance of the rare cannabinoid analogues developed by InMed’s division, BayMedica
In this discussion with The Dales Report, InMed CEO, Eric A. Adams talks about the commercial importance of the rare cannabinoid analogues developed by InMed’s...
Source:
The Dales Report
October 28, 2021
InMed’s Shane Johnson Speaks at Edison Open Forum Cannabinoids 2021
Shane Johnson, InMed’s Senior VP and BayMedica’s General Manager, joins the Edison Open Forum Cannabinoids 2021 Event. In his interview, Shane talks about InMed and...
Source:
Edison